CBIO
Crescent Biopharma, Inc. Common Stock
stockNASDAQ
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 13.06 | 2026-11-03 | +4.33% | 1.477 |
| 1M | 14.91 | 2026-10-09 | -8.62% | 1.773 |
| 3M | 17.33 | 2026-08-10 | -21.38% | 1.720 |
| 6M | 18.52 | 2026-05-11 | -26.43% | 1.606 |
| 1Y | 13.11 | 2025-11-10 | +3.93% | 1.124 |
| 2Y | 15.80 | 2025-06-16 | -13.74% | — |
| 5Y | 45.75 | 2021-11-10 | -70.22% | 0.454 |
Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO) stock price today is $13.63, and today's volume is 75,831. CBIO is down 0.183% today. The 30 day average volume is 291,273. CBIO market cap is $506.13M with 37.15M shares outstanding.